Lixte Biotechnology Holdings (FRA:8640) Price-to-Tangible-Book : 30.20 (As of Apr. 28, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Price-to-Tangible-Book?

As of today (2024-04-28), Lixte Biotechnology Holdings's share price is €6.10. Lixte Biotechnology Holdings's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was €0.20. Hence, Lixte Biotechnology Holdings's Price to Tangible Book Ratio of today is 30.20.

The historical rank and industry rank for Lixte Biotechnology Holdings's Price-to-Tangible-Book or its related term are showing as below:

FRA:8640' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.09 Med: 19.35 Max: 99.7
Current: 14.82

During the past 13 years, Lixte Biotechnology Holdings's highest Price to Tangible Book Ratio was 99.70. The lowest was 5.09. And the median was 19.35.

FRA:8640's Price-to-Tangible-Book is ranked worse than
93.28% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs FRA:8640: 14.82

A closely related ratio is called PB Ratio. As of today, Lixte Biotechnology Holdings's share price is €6.10. Lixte Biotechnology Holdings's Book Value per Sharefor the quarter that ended in Dec. 2023 was €0.20. Hence, Lixte Biotechnology Holdings's P/B Ratio of today is 30.20.

Lixte Biotechnology Holdings Price-to-Tangible-Book Historical Data

The historical data trend for Lixte Biotechnology Holdings's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Price-to-Tangible-Book Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

12.29

4.64

Lixte Biotechnology Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															4.64	22.70	-	10.29	-

Competitive Comparison of Lixte Biotechnology Holdings's Price-to-Tangible-Book

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Price-to-Tangible-Book falls into.

Lixte Biotechnology Holdings Price-to-Tangible-Book Calculation

Lixte Biotechnology Holdings's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	6.10	/	0.202
	=	30.20

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Lixte Biotechnology Holdings Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (FRA:8640) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines